Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Convalescent Plasma  COVID-19 treatment studies for Conv. Plasma  C19 studies: Conv. Plasma  Conv. Plasma   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
All Studies   All Outcomes   Recent:  
0 0.5 1 1.5 2+ Mortality, day 60 37% Improvement Relative Risk Mortality, day 21 14% Recovery 16% primary c19early.org/cp Körper et al. NCT04433910 CAPSID Conv. Plasma RCT LATE Favors conv. plasma Favors control
Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19
Körper et al., Journal of Clinical Investigation, doi:10.1172/JCI152264, CAPSID, NCT04433910 (history)
Körper et al., Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19, Journal of Clinical Investigation, doi:10.1172/JCI152264, CAPSID, NCT04433910
Oct 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
RCT 105 hospitalized patients in Germany, 53 treated with convalescent plasma, showing no significant difference in mortality or the primary composite outcome of survival and no longer fulfilling criteria for severe COVID-19 on day 21.
risk of death, 36.5% lower, RR 0.63, p = 0.19, treatment 11 of 53 (20.8%), control 17 of 52 (32.7%), NNT 8.4, day 60.
risk of death, 14.2% lower, RR 0.86, p = 0.79, treatment 7 of 53 (13.2%), control 8 of 52 (15.4%), NNT 46, day 21.
risk of no recovery, 15.9% lower, RR 0.84, p = 0.32, treatment 30 of 53 (56.6%), control 35 of 52 (67.3%), NNT 9.3, composite outcome of survival and no longer fulfilling criteria for severe COVID-19, day 21, primary outcome.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Körper et al., 15 Oct 2021, Randomized Controlled Trial, Germany, peer-reviewed, median age 60.0, 27 authors, trial NCT04433910 (history) (CAPSID).
All Studies   All Outcomes   Submit Updates or Corrections
This PaperConv. PlasmaAll
Abstract: CLINICAL MEDICINE The Journal of Clinical Investigation   Results of the CAPSID randomized trial for high-dose convalescent plasma in patients with severe COVID-19 Sixten Körper,1 Manfred Weiss,2 Daniel Zickler,3 Thomas Wiesmann,4 Kai Zacharowski,5 Victor M. Corman,6 Beate Grüner,7 Lucas Ernst,3 Peter Spieth,8 Philipp M. Lepper,9 Martin Bentz,10 Sebastian Zinn,5 Gregor Paul,11 Johannes Kalbhenn,12 Matthias M. Dollinger,13 Peter Rosenberger,14 Thomas Kirschning,15 Thomas Thiele,16 Thomas Appl,1 Benjamin Mayer,17 Michael Schmidt,18 Christian Drosten,6 Hinnerk Wulf,4 Jan Matthias Kruse,3 Bettina Jungwirth,2 Erhard Seifried,18 and Hubert Schrezenmeier1 for the CAPSID Clinical Trial Group19 Institute for Clinical Transfusion Medicine and Immunogenetics Ulm, German Red Cross Blood Transfusion Service Baden-Württemberg–Hessen and University Hospital Ulm, and Institute of Transfusion 1 Medicine, and 2Department of Anaesthesiology and Intensive Care Medicine, University Hospital Ulm, Ulm University, Ulm, Germany. 3Department of Nephrology and Medical Intensive Care, Charité – Universitätsmedizin Berlin, corporate member of Free University Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Berlin, Germany. 4Department of Anaesthesiology and Intensive Care Medicine, Philipps University Marburg, Marburg, Germany. 5Clinic of Anaesthesiology, Intensive Care Medicine and Pain Therapy, University Hospital Frankfurt, Frankfurt, Germany. 6Institute of Virology, Charité – Universitätsmedizin Berlin, corporate member of Free University Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health and German Centre for Infection Research, Berlin, Germany. Division of Infectious Diseases, University Hospital and Medical Center Ulm, Ulm, Germany. 8Department of Anesthesiology and Critical Care Medicine, Carl Gustav Carus University Hospital, Technische 7 Universität Dresden, Dresden, Germany. 9Department of Internal Medicine V – Pneumology, Allergology, Intensive Care Medicine, Saarland University Hospital, Homburg, Germany. 10Department of Internal Medicine III, Hospital of Karlsruhe, Karlsruhe, Germany. 11Department of Gastroenterology, Hepatology, Pneumology and Infectious Diseases, Klinikum Stuttgart, Stuttgart, Germany. 12Department of Anesthesiology and Critical Care, Medical Center – University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany. 13Medical Clinic I, Klinikum Landshut, Landshut, Germany. Department of Anesthesiology and Intensive Care Medicine, University Hospital Tübingen, Tübingen, Germany. 15Department of Anaesthesiology and Surgical Intensive Care Medicine, University of 14 Heidelberg, University Medical Centre Mannheim, Mannheim, Germany. 16Institute of Immunology and Transfusion Medicine, University Hospital Greifswald, Greifswald, Germany. 17Institute of Epidemiology and Medical Biometry, Ulm University, Ulm, Germany. 18Institute of Transfusion Medicine and Immunohematology, German Red Cross Blood Transfusion Service Baden-Württemberg–Hessen, Frankfurt, Germany. 19All members of the CAPSID Clinical Trial Group are listed in Supplemental Acknowledgments (supplemental material available online with this article; https://doi.org/10.1172/JCI152264DS1). BACKGROUND. COVID-19 convalescent plasma (CCP) has been considered a treatment option for COVID-19. This trial assessed the efficacy of a neutralizing antibody containing high-dose CCP in hospitalized adults with COVID-19..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit